Biju Parekkadan


“Cell Therapy and Drug Delivery”


Dr. Parekkadan is an Associate Professor of Biomedical Engineering with a laboratory that specializes in cell, gene, and tissue engineering. He has experience in developing biotech products as a founder of Sentien, a clinical stage pioneer of ex vivo cell therapeutics, as well as advising several companies. Dr. Parekkadan received his doctoral degree in Chemical and Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology, where he also completed all medical degree studies. His efforts have been recognized through notable awards including being named Young Mentor of the Year by Harvard Medical School and a Presidential Early Career Scientist from the Office of the White House, the highest honor of an early stage investigator.


Mesenchymal stem cells (MSCs) have long been shown to secrete potent immunomodulatory
molecules and extracellular vesicles. However, delivery of these cells has yielded limited
success in clinical applications thus far, likely due to ineffective dosing and limited exposure
times. Here, we present a biophysical model of MSC-immune interactions and a miniaturized bioreactor system to controlled delivery of MSC-produced factors. Results will be presented using a scalable bioreactor system to study inflamed blood cells within an in vitro setting as well in vivo testing in large animals and humans for the
treatment of autoinflammatory conditions.